Janux Therapeutics (JANX) News Today $48.76 -2.34 (-4.58%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period William Blair Reiterates "Outperform" Rating for Janux Therapeutics (NASDAQ:JANX)November 16 at 3:33 AM | americanbankingnews.comWilliam Blair Analysts Decrease Earnings Estimates for JANXNovember 13, 2024 | americanbankingnews.comHC Wainwright Expects Lower Earnings for Janux TherapeuticsNovember 12, 2024 | americanbankingnews.comHC Wainwright Has Negative Outlook of JANX FY2024 EarningsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings estimates for Janux Therapeutics in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now anticipates that theNovember 11, 2024 | marketbeat.comWilliam Blair Predicts Lower Earnings for Janux TherapeuticsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - William Blair lowered their FY2024 EPS estimates for shares of Janux Therapeutics in a research note issued on Wednesday, November 6th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($1.28) per share forNovember 11, 2024 | marketbeat.comJanux Therapeutics Inc (JANX) Receives a Buy from Cantor FitzgeraldNovember 8, 2024 | markets.businessinsider.comPromising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics’ JANX007 in mCRPC TreatmentNovember 7, 2024 | markets.businessinsider.comJanux Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 6, 2024 | businesswire.comNisa Investment Advisors LLC Increases Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Nisa Investment Advisors LLC lifted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 639.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 20,343 shares of the company's stock after buying an additional 17,592 shares durNovember 5, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Up 6.3% - What's Next?Janux Therapeutics (NASDAQ:JANX) Trading Up 6.3% - Still a Buy?November 4, 2024 | marketbeat.comPromising Outlook for Janux Therapeutics Ahead of Key Phase 1 Data ReleaseNovember 1, 2024 | markets.businessinsider.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Moderate Buy" from BrokeragesJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued aNovember 1, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 SharesOctober 31, 2024 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) Sees Significant Increase in Short InterestJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 4,330,000 shares, a growth of 25.1% from the September 30th total of 3,460,000 shares. Based on an average daily volume of 577,200 shares, the short-interest ratio is presently 7.5 days. Currently, 10.7% of the company's stock are short sold.October 30, 2024 | marketbeat.comJanux Therapeutics initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationOctober 25, 2024 | msn.comJanux Therapeutics (NASDAQ:JANX) Stock, Short Interest ReportOctober 24, 2024 | benzinga.comJanux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. Buys 1,200,000 SharesOctober 23, 2024 | insidertrades.comRA Capital Management Reduces Stake in Janux TherapeuticsOctober 22, 2024 | finance.yahoo.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC decreased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 83.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,738 shares of the company's stoOctober 21, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 1,843 SharesOctober 19, 2024 | insidertrades.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 3.6% - Should You Sell?Janux Therapeutics (NASDAQ:JANX) Shares Down 3.6% - Time to Sell?October 16, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Up 6.6% - Time to Buy?Janux Therapeutics (NASDAQ:JANX) Trading Up 6.6% - Still a Buy?October 15, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 234.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,048 shares of the company's stock after acquiOctober 14, 2024 | marketbeat.comJanux Therapeutics, Inc. (JANX): A Hot Stock to Buy NowOctober 8, 2024 | uk.finance.yahoo.comAmerican Century Companies Inc. Cuts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)American Century Companies Inc. reduced its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 79.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,627 shares of the company's stock after selling 21,428 sharOctober 5, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading 3.5% Higher Janux Therapeutics (NASDAQ:JANX) Trading 3.5% HigherOctober 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Acquires Shares of 136,430 Janux Therapeutics, Inc. (NASDAQ:JANX)Point72 Asset Management L.P. bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 136,430 shares of the company's sOctober 2, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 958 SharesOctober 1, 2024 | insidertrades.comBlue Owl Capital Holdings LP Acquires Shares of 40,000 Janux Therapeutics, Inc. (NASDAQ:JANX)Blue Owl Capital Holdings LP bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 40,000 shares of the company's stock, valued at approxSeptember 28, 2024 | marketbeat.comWoolworths CEO's heated confrontations: Credibility at all time lowSeptember 27, 2024 | au.finance.yahoo.comIs Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024?September 27, 2024 | msn.comProfund Advisors LLC Takes $598,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Profund Advisors LLC acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,274 shares of the company's stock, valued at approximately $598,000September 26, 2024 | marketbeat.comSamlyn Capital LLC Purchases 28,312 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Samlyn Capital LLC boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 9.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 324,703 shares of the company's stock after buyingSeptember 24, 2024 | marketbeat.comHighVista Strategies LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)HighVista Strategies LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 23,332 shares of the company's stock, vaSeptember 23, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Holdings Lifted by Rhumbline AdvisersRhumbline Advisers boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 41.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,008 shares of the company's stockSeptember 21, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Down 3.6% Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.6%September 17, 2024 | marketbeat.comRA Capital Management L.P. Increases Stake in Janux Therapeutics IncSeptember 17, 2024 | finance.yahoo.comJanux Therapeutics (NASDAQ:JANX) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Monday.September 16, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $7,427,457.00 in StockSeptember 15, 2024 | insidertrades.com19,800 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by TD Asset Management IncTD Asset Management Inc bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,800 shares of the company's stock, valued at approxSeptember 15, 2024 | marketbeat.comBank of New York Mellon Corp Purchases 66,340 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Bank of New York Mellon Corp boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 136.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,027 shares of the company's stock after acquiringSeptember 14, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Moderate Buy" from AnalystsJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned aSeptember 12, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 2,182 SharesSeptember 11, 2024 | insidertrades.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells 2,182 Shares of StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the completion of the sale, the insider now directly owns 7,000 shares in the company, valued at $296,310. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.September 10, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading 4.9% Higher Janux Therapeutics (NASDAQ:JANX) Shares Up 4.9%September 10, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Candriam S.C.A.Candriam S.C.A. increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 40.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,004 shares of the company's stock afterSeptember 10, 2024 | marketbeat.comStifel Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationSeptember 8, 2024 | msn.comNavigating 5 Analyst Ratings For Janux TherapeuticsSeptember 6, 2024 | benzinga.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up to $43.71Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $43.71September 6, 2024 | marketbeat.com Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. Related Videos JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼-0.330.55▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼133▲JANX Articles Average Week Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRRK News Today PRAX News Today IGMS News Today FHTX News Today OCGN News Today PSTX News Today NKTR News Today CRBU News Today ACRS News Today RPTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
